Soteras Health Company

Ticker: SHC

Class Period Start: 11/20/2020

Class Period End: 09/19/2022

Registration Deadline: 03/27/2023

Submit Your Information
A securities class action has been filed in the USDC – N.D.OH. against Sotera Health Company (SHC) on behalf of all persons or entities that purchased or otherwise acquired Sotera common stock: (i) pursuant and/or traceable to the Company’s initial public offering conducted on or around November 20, 2020 (the “IPO”); (ii) pursuant and/or traceable to the Company’s secondary public offering conducted on or around March 18, 2021 (the “SPO,” and together with the IPO, the “Offerings”); and/or (iii) between November 20, 2020 through September 19, 2022.  

Sotera provides sterilization solutions, lab testing, and advisory services for the healthcare and pharmaceutical industries. Through its Sterigenics brand, Sotera provides sterilization services for the medical device and pharmaceutical markets. The Company uses Ethylene Oxide (“EtO”) processing as one of three methods to sterilize products. EtO processing is a gas sterilization process in which pallets of packaged goods are loaded into a chamber that is then injected with EtO gas to penetrate the packaging. That process emits toxic fumes which must be filtered before being released into the air. Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities throughout the United States, including Illinois, California, Georgia, and New Mexico, among other places.

The Complaint alleges that, throughout the Class Period, and in connection with the IPO and the SPO, the Company made numerous materially false and misleading representations concerning its emissions control systems and exposure to liability from lawsuits for the Company’s failure to limit harmful Ethylene Oxide (“EtO”) emissions. The Company represented that it had “a proactive [environmental, health and safety] program and a culture of safety and quality.” In addition, the Company stated that it employed adequate and effective safeguards to control EtO emissions. Moreover, the Company and its executives vehemently denied allegations that the Company’s EtO emissions from its sterilization facilities caused cancer and other severe health issues in people living in the communities near those facilities. In truth, the Company and its senior executives and controlling shareholders knew, or at a minimum, recklessly disregarded, that for years the Company failed to employ effective emissions control systems to prevent the release of excessive amounts of toxic EtO gas from its sterilization facilities. Those deficiencies exposed people living in the surrounding communities to a significantly increased risk of cancer and subjected the Company to an increased risk of liability from hundreds of EtO-related lawsuits.

Investors began to learn the truth on September 19, 2022, when an Illinois state court jury in the first lawsuit arising from the Company’s EtO emissions to go to trial. As a result of these disclosures, Sotera’s stock price declined by $4.90 per share, or 33.3%, from $14.73 per share on September 16, 2022, to $9.83 per share on September 19, 2022.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Purchases

Sales

Please Note

Neither the submission to nor the receipt of information by Lowey Dannenberg or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* Indicates a required field.

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.